Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609814 | 0.89 | NAMPT (0.52) | NAMPTMAPKAPK2NPC1RAB9APAX8 | |
| Acetic Acid SCHEMBL28111547 | 0.85 | NAMPT (0.49) | NAMPTMAPKAPK2NPC1RAB9APAX8 | |
| SCHEMBL7078666 | 0.82 | MAPT (0.51) | NAMPTCYP17A1SMN1; SMN2PSMB8 | |
| SCHEMBL7324243 | 0.80 | NAMPT (0.46) | NAMPTMAPKAPK2NPC1RAB9APAX8 | |
| SCHEMBL24364346 | 0.80 | PTPN11 (0.51) | NAMPTMAPKAPK2NPC1RAB9APAX8 | |
| SCHEMBL30884737 | 0.79 | NAMPT (0.49) | NAMPTMAPKAPK2CYP17A1PSMB8MAP4K4 | |
| SCHEMBL5778192 | 0.79 | NAMPT (0.49) | NAMPTMAPKAPK2CYP17A1PSMB8MAP4K4 | |
| SCHEMBL392294 | 0.79 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1PSMB8MAP4K4 | |
| SCHEMBL29491458 | 0.79 | NAMPT (0.51) | NAMPTMAPKAPK2CYP17A1PSMB8MAP4K4 | |
| SCHEMBL24756649 | 0.78 | ALDH1A1 (0.51) | NAMPTNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555561-B2 | N-(5-((((5-Chloro-2,4-dimethoxyphenyl)amino)thioxomethyl)-amino)-2 -pyridinyl)-2-methylbenzamide, for example; inhibiting replication of a herpes virus | WYETH | 2003-04-29 | — | — | US | disclosed |
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2003-02-20 | — | — | US | disclosed |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-28 | — | — | US | disclosed |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | HAVCR2, CCR6, CXCR6 | NAMPT 3260/4885MAPKAPK2 3243/4885NPC1 1705/4885 |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | CCR6, HAVCR2, BCOR | NAMPT 3999/4885MAPKAPK2 4012/4885NPC1 797/4885 |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | TK1, TPMT, CXCR6 | NAMPT 4031/4885MAPKAPK2 3654/4885NPC1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.